
|Articles|October 1, 2003
New Products & Services
Once-daily quinolone gains new urology indications: West Haven, CT-Bayer Pharmaceuticals has received FDA approval to market its once-daily, extended-release fluoroquinolone, ciprofloxacin (Cipro XR), for two new indications: complicated urinary tract infections and acute uncomplicated pyelonephritis.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants priority review to sBLA for EV plus pembrolizumab in cisplatin-ineligible MIBC
2
Kim Nguyen Chi, MD, on 177Lu-PSMA-617 vs docetaxel in mCRPC
3
Adjuvant durvalumab plus tremelimumab after RCC resection improves DFS
4
News Network: Prostate Cancer and Bladder Cancer at ESMO 2025
5